Information  X 
Enter a valid email address

Diurnal Group PLC Ord GBP0.05 (DNL)

Date Time Source Announcement
26 Jul 2022 7:00 am
RNS
Trading Update
15 Jul 2022 12:04 pm
RNS
Director Dealings
30 Jun 2022 1:29 pm
RNS
Block Listing Six Monthly Return
07 Jun 2022 1:00 pm
RNS
Diurnal to present research at ENDO 2022
01 Jun 2022 7:00 am
RNS
First patient dosed in pivotal Phase 3 trial
23 May 2022 8:41 am
RNS
Correction: Presentation at ECE
09 May 2022 12:49 pm
RNS
Director Dealings
29 Apr 2022 3:37 pm
RNS
Total Voting Rights
28 Apr 2022 7:00 am
RNS
Diurnal to present at Investor Evening
25 Apr 2022 7:00 am
RNS
Distribution agreement signed with EffRx
20 Apr 2022 7:00 am
RNS
Distribution agreement signed with Er-Kim
04 Apr 2022 7:00 am
RNS
Directorate Change and Management Updates
01 Apr 2022 7:00 am
RNS
Total Voting Rights
30 Mar 2022 7:00 am
RNS
Distribution agreement with Vector Pharma
22 Mar 2022 4:35 pm
RNS
Price Monitoring Extension
  2:06 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Interim Results
09 Mar 2022 7:00 am
RNS
Interim Results Investor Presentation
07 Mar 2022 2:30 pm
RNS
Scottish Medicines Consortium Update
02 Mar 2022 7:00 am
RNS
Regulatory update on oral native testosterone
01 Mar 2022 10:23 am
RNS
Total Voting Rights
24 Feb 2022 12:00 pm
RNS
Notice of Interim Results
10 Feb 2022 7:00 am
RNS
First patient dosed in Phase 2 trial
09 Feb 2022 7:00 am
RNS
Issue of Long-Term Incentive Plan awards
01 Feb 2022 7:00 am
RNS
Total Voting Rights
31 Jan 2022 1:26 pm
RNS
Postponement of R&D Day
26 Jan 2022 7:00 am
RNS
Trading Update
24 Jan 2022 7:00 am
RNS
Diurnal to participate in Edison "Open House"
11 Jan 2022 7:00 am
RNS
Operational update
07 Jan 2022 12:58 pm
RNS
Holding(s) in Company
13 Dec 2021 12:46 pm
RNS
Block Admission Application
02 Dec 2021 7:00 am
RNS
Notice of R&D Day
19 Nov 2021 11:43 am
RNS
Results of AGM
16 Nov 2021 7:00 am
RNS
Alkindi approved for use in Switzerland
15 Nov 2021 5:20 pm
RNS
Eton enters into US co-promotion deal
  7:00 am
RNS
Directorate Change
08 Nov 2021 9:16 am
RNS
Holding(s) in Company
15 Oct 2021 11:17 am
RNS
Holding(s) in Company
14 Oct 2021 7:01 am
RNS
Appointment of Joint Corporate Broker
  7:00 am
RNS
Agreement signed with ExCEEd Orphan for CEE
11 Oct 2021 7:00 am
RNS
Phase 1 data for DITEST published in EJE
08 Oct 2021 12:24 pm
RNS
Exercise of Options, Issue of Equity and TVR
07 Oct 2021 11:15 am
EQS
Hardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
06 Oct 2021 3:53 pm
RNS
Posting of Annual Report and Notice of AGM
30 Sep 2021 12:08 pm
RNS
Holding(s) in Company
29 Sep 2021 2:35 pm
RNS
Holding(s) in Company
17 Sep 2021 7:00 am
RNS
Hardman & Co Life Sciences Investor Forum
16 Sep 2021 10:15 am
EQS
Diurnal Group (DNL): All set for three pivotal trials
15 Sep 2021 9:17 am
RNS
Director Dealings
14 Sep 2021 7:00 am
RNS
Results for the year ended 30 June 2021
13 Sep 2021 7:00 am
RNS
Commercial launch of Efmody in the UK
01 Sep 2021 7:00 am
RNS
Diurnal launches Efmody in Germany and Austria
19 Aug 2021 7:00 am
RNS
Full Year Results Investor Presentation
12 Aug 2021 7:20 am
EQS
Hardman & Co Video Event | Diurnal Group plc - Investor Forum
02 Aug 2021 7:00 am
RNS
Grant of Deferred Share Awards
28 Jul 2021 7:00 am
RNS
Business and Trading Update
14 Jul 2021 7:00 am
RNS
Director Dealings
12 Jul 2021 7:00 am
RNS
Agreement from US FDA on SPA for Chronocort
09 Jul 2021 8:30 am
RNS
Director Dealings and Issue of Equity

a d v e r t i s e m e n t